References
- Andreasen, N. C. 1983a. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa.
- Andreasen, N. C. 1983b. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa.
- Andrews, N., and H. Cho. 2018. Validating effectiveness of subgroup identification for longitudinal data. Statistics in Medicine 37:98–106. doi:https://doi.org/10.1002/sim.7500.
- Barrigón, M. L., M. Gurpegui, M. Ruiz-Veguilla, F. J. Diaz, M. Anguita, F. Sarramea, and J. Cervilla. 2010. Temporal relationship of first-episode non-affective psychosis with cannabis use: A clinical verification of an epidemiological hypothesis. Journal of Psychiatric Research 44:413–420. doi:https://doi.org/10.1016/j.jpsychires.2009.10.004.
- Bernardo, J. M., and A. F. M. Smith. 1994. Bayesian theory. New York: Wiley.
- Bhattacharyya, S., Z. Atakan, R. Martin-Santos, J. A. Crippa, J. Kambeitz, S. Malhi, V. Giampietro, S. Williams, M. Brammer, K. Rubia, et al. 2015. Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis. European Neuropsychopharmacology 25:26–37. doi:https://doi.org/10.1016/j.euroneuro.2014.11.018.
- Bhattacharyya, S., Z. Atakan, R. Martin-Santos, J. A. Crippa, J. Kambeitz, D. Prata, S. Williams, M. Brammer, D. A. Collier, and P. K. McGuire (2012). Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function. Molecular Psychiatry 17:1152–1155.
- Bhattacharyya, S., P. Fusar-Poli, S. Borgwardt, R. Martin-Santos, C. Nosarti, C. O’Carroll, P. Allen, M. L. Seal, P. C. Fletcher, J. A. Crippa, et al. 2009. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: A neural basis for the effects of Cannabis sativa on learning and psychosis. Archives of General Psychiatry 66:442–451. doi:https://doi.org/10.1001/archgenpsychiatry.2009.17.
- Bock, R. D., and M. Aitkin. 1981. Marginal maximum likelihood an EM algorithm. Psychometrika 46:443–459. doi:https://doi.org/10.1007/BF02293801.
- Botts, S., F. J. Diaz, V. Santoro, E. Spina, M. R. Muscatello, M. Cogollo, F. E. Castro, and J. de Leon. 2008. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Progress in Neuro-psychopharmacology & Biological Psychiatry 32:1453–1458. doi:https://doi.org/10.1016/j.pnpbp.2008.04.018.
- Boulesteix, A. L., R. De Bin, X. Jiang, and M. Fuchs. 2017. IPF-LASSO: Integrative L(1)-penalized regression with penalty factors for estimation based on multi-omics data. Computational and Mathematical Methods in Medicine (2017:7691937.
- Brim, R. L., and F. G. Miller. 2013. The potential benefit of the placebo effect in sham-controlled trials: Implications for risk-benefit assessments and informed consent. Journal of Medical Ethics 39:703–707. doi:https://doi.org/10.1136/medethics-2012-101045.
- Carlin, B. R., and T. A. Louis. 2000a. Bayes and Empirical Bayes Methods for Data Analysis. 2nd ed. (edition) Boca Raton: Chapman and Hall-CRC.
- Carlin, B. R., and T. A. Louis. 2000b. Empirical Bayes: Past, present and future. Journal of American Statistical Association 95:1286–1289. doi:https://doi.org/10.1080/01621459.2000.10474331.
- Caspari, D. 1999. Cannabis and schizophrenia: Results of a follow-up study. European Archives of Psychiatry and Clinical Neurosciences 249:45–49. doi:https://doi.org/10.1007/s004060050064.
- Cho, H., P. Wang, and A. Qu. 2017. Personalized treatment for longitudinal data using unspecified random-effects model. Statistica Sinica 27:187–205.
- Clausen, L., C. R. Hjorthøj, A. Thorup, P. Jeppesen, L. Petersen, M. Bertelsen, and M. Nordentoft. 2014. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: A 5-year follow-up study of patients in the OPUS trial. Psychological Medicine 44:117–126. doi:https://doi.org/10.1017/S0033291713000433.
- Cobo, B., M. M. Rueda, and F. López-Torrecillas. 2017. Application of randomized response techniques for investigating cannabis use by Spanish university students. International Journal of Methods in Psychiatric Research 26:4. doi:https://doi.org/10.1002/mpr.1517.
- de Leon, J. 2012. Evidence-based medicine versus personalized medicine: Are they enemies? Journal of Clinical Psychopharmacology 32:153–164. doi:https://doi.org/10.1097/JCP.0b013e3182491383.
- Dekker, N., M. Koeter, W. Den Brink, and G.R.O.U.P. Investigators. 2012. Craving for cannabis in patients with psychotic disorder, their non-affected siblings and healthy controls: Psychometric analysis of the obsessive-compulsive drug use scale. International Journal of Methods in Psychiatric Research 21:286–300. doi:https://doi.org/10.1002/mpr.1362.
- Diaz, F. J. 2016. Measuring the individual benefit of a medical or behavioral treatment using generalized linear mixed-effects models. Statistics in Medicine 35:4077–4092. doi:https://doi.org/10.1002/sim.7005.
- Diaz, F. J. 2018. Construction of the design matrix for generalized linear mixed-effects models in the context of clinical trials of treatment sequences. Revista Colombiana De Estadística 41:191–233. doi:https://doi.org/10.15446/rce.v41n2.63332.
- Diaz, F. J. 2019. Estimating individual benefits of medical or behavioral treatments in severely ill patients. Statistical Methods in Medical Research 28:911–927. doi:https://doi.org/10.1177/0962280217739033.
- Diaz, F. J., M. J. Berg, R. Krebill, T.Welty, B. E. Gidal, R. Alloway, and M. Privitera. 2013a. Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: The four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designs. Clinical Pharmacokinetics 52:1033–1043. doi:https://doi.org/10.1007/s40262-013-0103-4.
- Diaz, F. J., M. R. Cogollo, E. Spina, V. Santoro, D. M. Rendon, and J. de Leon. 2012a. Drug dosage individualization based on a random-effects linear model. Journal of Biopharmaceutical Statistics 22:463–484. doi:https://doi.org/10.1080/10543406.2010.547264.
- Diaz, F. J., and J. de Leon. 2013b. The mathematics of drug dose individualization should be built with random effects linear models. Therapeutic Drug Monitoring 35:276–277. doi:https://doi.org/10.1097/FTD.0b013e318283e3c6.
- Diaz, F. J., C. B. Eap, N. Ansermot, S. Crettol, E. Spina, and J. de Leon. 2014. Can valproic acid be an inducer of clozapine metabolism? Pharmacopsychiatry 47:89–96. doi:https://doi.org/10.1055/s-0034-1371866.
- Diaz, F. J., T. E. Rivera, R. C. Josiassen, and J. de Leon. 2007. Individualizing drug dosage by using a random intercept linear model. Statistics in Medicine 26:2052–2073. doi:https://doi.org/10.1002/sim.2636.
- Diaz, F. J., V. Santoro, E. Spina, M. Cogollo, T. E. Rivera, S. Botts, and J. de Leon. 2008. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 41:81–91. doi:https://doi.org/10.1055/s-2007-1004591.
- Diaz, F. J., H.-W. Yeh, and J. de Leon. 2012b. Role of statistical random-effects linear models in personalized medicine. Current Pharmacogenomics and Personalized Medicine 10:22–32. doi:https://doi.org/10.2174/1875692111201010022.
- Efron, B., and C. Morris. 1973. Stein’s estimation rule and its competitors - an empirical Bayes approach. Journal of American Statistical Association 68 (34):117–130.
- Efron, B., and C. Morris. 1975. Data analysis using Stein’s estimator and its generalizations. Journal of American Statistical Association 70 (35):311–319. doi:https://doi.org/10.1080/01621459.1975.10479864.
- Emerson, P. L. 1968. Numerical construction of orthogonal polynomials from a general recurrence formula. Biometrics 24:695–701. doi:https://doi.org/10.2307/2528328.
- Foti, D. J., R. Kotov, L. T. Guey, and E. J. Bromet. 2010. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. American Journal of Psychiatry 167:987–993. doi:https://doi.org/10.1176/appi.ajp.2010.09020189.
- Frees, E. W. 2004. Longitudinal and Panel Data: Analysis and Applications in the Social Sciences. Cambridge, UK: Cambridge University Press.
- Gewandter, J. S., M. P. McDermott, H. He, S. Gao, X. Cai, J. T. Farrar, N. P. Katz, J. D. Markman, S. Senn, D. C. Turk, et al. 2019. Demonstrating heterogeneity of treatment effects among patients: An overlooked but important step toward precision medicine. Clinical Pharmacology and Therapeutics 106:204–210. doi:https://doi.org/10.1002/cpt.1372.
- Goldstein, B. A., A. M. Navar, and R. E. Carter. 2017. Moving beyond regression techniques in cardiovascular risk prediction: Applying machine learning to address analytic challenges.. European Heart Journal 38 (23):1805–1814. doi:https://doi.org/10.1093/eurheartj/ehw302.
- Grech, A., J. Van Os, P. B. Jones, S. W. Lewis, and R. M. Murray. 2005. Cannabis use and outcome of recent onset psychosis. European Psychiatry 20:349–353. doi:https://doi.org/10.1016/j.eurpsy.2004.09.013.
- Hamming, R. W. 1987. Numerical Methods for Scientists and Engineers (2nd ed). Mineola, NY: Dover.
- Hedeker, D., and R. D. Gibbons. 2006. Longitudinal Data Analysis. Hoboken, NJ: Wiley.
- Hides, L., S. Dawe, D. J. Kavanagh, and R. M. Young. 2006. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. British Journal of Psychiatry 189:137–143. doi:https://doi.org/10.1192/bjp.bp.105.014308.
- Hoijtink, H., and A. Boomsma. 1995. On person parameter estimation in the dichotomous Rasch model. In Rasch Models: Foundations, Recent Developments, and Applications, ed. G. H. Fischer and I. W. Molenaar, 53–68. New York: Springer.
- Iddi, S., G. Molenberghs, M. Aregay, and G. Kalema. 2014. Empirical Bayes estimates for correlated hierarchical data with overdispersion. Pharmaceutical Statistics 13:316–326. doi:https://doi.org/10.1002/pst.1635.
- Kim, S., V. Baladandayuthapani, and J. J. Lee. 2017. Estimation-oriented marker selection (PROMISE): With application to high-dimensional regression. Statistics in Biosciences 9:217–245. doi:https://doi.org/10.1007/s12561-016-9169-5.
- Kuepper, R., J. van Os, R. Lieb, H. U. Wittchen, M. Höfler, and C. Henquet. 2011. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. British Medical Journal 342:d738. doi:https://doi.org/10.1136/bmj.d738.
- Legleye, S. 2018. The cannabis abuse screening test and the DSM-5 in the general population: Optimal thresholds and underlying common structure using multiple factor analysis. International Journal of Methods in Psychiatric Research 27:e1597. doi:https://doi.org/10.1002/mpr.1597.
- Linszen, D. H., P. M. Dingemans, and M. E. Lenior. 1994. Cannabis abuse and the course of recent onset schizophrenic disorders. Archives of General Psychiatry 51:273–279. doi:https://doi.org/10.1001/archpsyc.1994.03950040017002.
- Linszen, D. H., P. M. Dingemans, M. A. Nugter, A. J. Van der Does, W. F. Scholte, and M. A. Lenior. 1997. Patient attributes and expressed emotion as risk factors for psychotic relapse. Schizophrenia Bulletin 23:119–130. doi:https://doi.org/10.1093/schbul/23.1.119.
- Ma, J., F. C. Stingo, and B. P. Hobbs. 2016. Bayesian predictive modeling for genomic based personalized treatment selection. Biometrics 72:575–583. doi:https://doi.org/10.1111/biom.12448.
- Marder, S. R., J. M. Davis, and G. Chouinard. 1997. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. The Journal of Clinical Psychiatry 58:538–546. doi:https://doi.org/10.4088/JCP.v58n1205.
- Maritz, J. S., and T. Lwin. 1989. Empirical Bayes Methods. London: Chapman and Hall.
- McCulloch, C. E., and J. M. Neuhaus. 2011a. Prediction of random effects in linear and generalized linear models under model misspecification. Biometrics 67:270–279. doi:https://doi.org/10.1111/j.1541-0420.2010.01435.x.
- McCulloch, C. E., and J. M. Neuhaus. 2011b. Misspecifying the shape of a random effects distribution: Why getting it wrong may not matter. Statistical Science 26:388–402. doi:https://doi.org/10.1214/11-STS361.
- Miller, F. G., and L. Colloca. 2009. The legitimacy of placebo treatments in clinical practice: Evidence and ethics. American Journal of Bioethics 9:39–47. doi:https://doi.org/10.1080/15265160903316263.
- Moore, T. H., S. Zammit, A. Lingford-Hughes, T. R. Barnes, P. B. Jones, M. Burke, and G. Lewis. 2007. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370:319–328. doi:https://doi.org/10.1016/S0140-6736(07)61162-3.
- Morris, C. 1983. Parametric empirical Bayes inference: Theory and applications. Journal of American Statistical Association 78:47–55. doi:https://doi.org/10.1080/01621459.1983.10477920.
- Neuhaus, J. M., W. W. Hauck, and J. D. Kalbfleisch. 1992. The effects of mixture distribution misspecification when fitting mixed-effects logistic-models. Biometrika 79:755–762. doi:https://doi.org/10.1093/biomet/79.4.755.
- Pelayo-Terán, J. M., F. J. Diaz, R. Pérez-Iglesias, P. Suárez-Pinilla, R. Tabarés-Seisdedos, J. de Leon, and B. Crespo-Facorro. 2014. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychological Medicine 44:37–50. doi:https://doi.org/10.1017/S0033291713000330.
- Pettofrezzo, A. J. 1984. Introductory Numerical Analysis. Mineola, NY: Dover.
- Powers, S., J. Qian, K. Jung, A. Schuler, N. H. Shah, T. Hastie, and R. Tibshirani. 2018. Some methods for heterogeneous treatment effect estimation in high dimensions. Statistics in Medicine 37:1767–1787. doi:https://doi.org/10.1002/sim.7623.
- Robinson, G. K. 1991. That BLUP is a good thing: The estimation of random effects. Statistical Science 6:15–32. doi:https://doi.org/10.1214/ss/1177011926.
- Ruberg, S. J., L. Chen, and Y. Wang. 2010. The mean does not mean as much anymore: Finding sub-groups for tailored therapeutics. Clinical Trials 7:574–583. doi:https://doi.org/10.1177/1740774510369350.
- Rubin, D. B. 1980. Using empirical Bayes techniques in the law school validity studies. Journal of American Statistical Association 75:801–827. doi:https://doi.org/10.1080/01621459.1980.10477553.
- Schoeler, T., J. Kambeitz, I. Behlke, R. Murray, and S. Bhattacharyya. 2016. The effects of cannabis on memory function in users with and without a psychotic disorder: Findings from a combined meta-analysis. Psychological Medicine 46:177–188. doi:https://doi.org/10.1017/S0033291715001646.
- Searle, S. R., G. Casella, and C. E. McCulloch. 1992. Variance Components. New York: Wiley.
- Senn, S. 2016. Mastering variation: Variance components and personalised medicine. Statistics in Medicine 35:966–977. doi:https://doi.org/10.1002/sim.6739.
- Shirafkan, H., J. Mahmoudi-Gharaei, A. Fotouhi, S. A. Mozaffarpur, M. Yaseri, and M. Hoseini. 2020. Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder. BMC Medical Research Methodology 20:56. doi:https://doi.org/10.1186/s12874-020-00934-y.
- Sies, A., K. Demyttenaere, and I. Van Mechelen. 2019. Studying treatment-effect heterogeneity in precision medicine through induced subgroups. Journal of Biopharmaceutical Statistics 29:491–507. doi:https://doi.org/10.1080/10543406.2019.1579220.
- Skrondal, A., and S. Rabe-Hesketh. 2004. Generalized Latent Variable Modeling: Multilevel, Longitudinal, and Structural Equation Models (1st edition). Boca Raton, FL: Chapman and Hall/CRC.
- Skrondal, A., and S. Rabe-Hesketh. 2009. Prediction in multilevel generalized linear models. Journal of the Royal Statistical Society Series A-Statistics in Society 172:659–687. doi:https://doi.org/10.1111/j.1467-985X.2009.00587.x.
- Wang, P., G. F. Tsai, and A. Qu. 2012. Conditional inference functions for mixed-effects models with unspecified random-effects distribution. Journal of the American Statistical Association 107:725–736. doi:https://doi.org/10.1080/01621459.2012.665199.
- Wang, Z. (2019).Prediction of random effects in mixed effects models under violations of the normality assumption for the random effects and a graphical approach to detect violations. Ph.D. Dissertation (Committee Chair, F.J. Diaz). Department of Biostatistics, The University of Kansas Medical Center, Kansas City, KS, United States.
- Warm, T. A. 1989. Weighted likelihood estimation of ability in item response models. Psychometrika 54:427–450. doi:https://doi.org/10.1007/BF02294627.
- White, I. R., E. Moodie, S. G. Thompson, and T. A. Croudace. 2003. Modelling strategy for the analysis of clinical trials with partly missing longitudinal data. International Journal of Methods in Psychiatric Research 12:139–150.
- Wilson, R. P., and S. Bhattacharyya. 2016. Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review. Journal of Psychopharmacology 30:99–111. doi:https://doi.org/10.1177/0269881115612237.
- Woodward, M. 2005. Epidemiology: Study Design and Data Analysis (2nd ed). Boca Raton, FL: Chapman & Hall/CRC.
- Xu, W., and D. Hedeker. 2001. A random-effects mixture model for classifying treatment response in longitudinal clinical trials. Journal of Biopharmaceutical Statistics 11:253–273. doi:https://doi.org/10.1081/BIP-120008848.
- Zammit, S., T. H. Moore, A. Lingford-Hughes, T. R. Barnes, P. B. Jones, M. Burke, and G. Lewis. 2008. Effects of cannabis use on outcomes of psychotic disorders: Systematic review. British Journal of Psychiatry 193:357–363. doi:https://doi.org/10.1192/bjp.bp.107.046375.
- Zhu, X., and A. Qu. 2016. Individualizing drug dosage with longitudinal data. Statistics in Medicine 35:4474–4488. doi:https://doi.org/10.1002/sim.7016.